Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F)
Brief Summary: This study will evaluate the efficacy of VX-445 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous for the F508del mutation (F/F)


Options:
A: Arm Label: TEZ/IVA; Type: ACTIVE_COMPARATOR; Interventions: Drug: TEZ/IVA, Drug: IVA, Drug: Placebo | Arm Label: VX-445/TEZ/IVA TC; Type: EXPERIMENTAL; Interventions: Drug: VX-445/TEZ/IVA, Drug: IVA, Drug: Placebo | Intervention Type: DRUG; Name: VX-445/TEZ/IVA; Assigned to Arm(s): VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: TEZ/IVA; Assigned to Arm(s): TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): TEZ/IVA, VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): TEZ/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): VX-445/TEZ/IVA TC
B: Arm Label: N91115 + Rifampin; Type: EXPERIMENTAL; Interventions: Drug: N91115, Drug: Rifampin | Intervention Type: DRUG; Name: N91115; Assigned to Arm(s): N91115 + Rifampin | Intervention Type: DRUG; Name: Rifampin; Assigned to Arm(s): N91115 + Rifampin
C: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
D: Arm Label: Cohort A: GLPG2222 50 mg once daily (QD); Type: EXPERIMENTAL; Interventions: Drug: GLPG2222 50 mg, Drug: Placebo | Arm Label: Cohort A: GLPG2222 100 mg QD; Type: EXPERIMENTAL; Interventions: Drug: GLPG2222 100 mg, Drug: Placebo | Arm Label: Cohort B: GLPG2222 200 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: GLPG2222 200 mg | Arm Label: Cohort B: GLPG2222 400 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: GLPG2222 400 mg | Arm Label: Cohort A Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort B Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GLPG2222 50 mg; Assigned to Arm(s): Cohort A: GLPG2222 50 mg once daily (QD) | Intervention Type: DRUG; Name: GLPG2222 100 mg; Assigned to Arm(s): Cohort A: GLPG2222 100 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort A Placebo, Cohort A: GLPG2222 100 mg QD, Cohort A: GLPG2222 50 mg once daily (QD), Cohort B Placebo, Cohort B: GLPG2222 200 mg QD, Cohort B: GLPG2222 400 mg QD | Intervention Type: DRUG; Name: GLPG2222 200 mg; Assigned to Arm(s): Cohort B: GLPG2222 200 mg QD | Intervention Type: DRUG; Name: GLPG2222 400 mg; Assigned to Arm(s): Cohort B: GLPG2222 400 mg QD

Answer: A